Cargando…

Liver-specific lncRNA FAM99A may be a tumor suppressor and promising prognostic biomarker in hepatocellular carcinoma

BACKGROUND: Increasing evidence shows that liver-specific long non-coding RNAs (lncRNAs) play important roles in the development of hepatocellular carcinoma (HCC). We identified a novel liver-specific lncRNA, FAM99A, and examined its clinical significance and biological functions in HCC. METHODS: Th...

Descripción completa

Detalles Bibliográficos
Autores principales: Mo, Meile, Ma, Xiaoyun, Luo, Yihuan, Tan, Chao, Liu, Bihu, Tang, Peng, Liao, Qian, Liu, Shun, Yu, Hongping, Huang, Dongping, Zeng, Xiaoyun, Qiu, Xiaoqiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9609286/
https://www.ncbi.nlm.nih.gov/pubmed/36289466
http://dx.doi.org/10.1186/s12885-022-10186-2
_version_ 1784818980279549952
author Mo, Meile
Ma, Xiaoyun
Luo, Yihuan
Tan, Chao
Liu, Bihu
Tang, Peng
Liao, Qian
Liu, Shun
Yu, Hongping
Huang, Dongping
Zeng, Xiaoyun
Qiu, Xiaoqiang
author_facet Mo, Meile
Ma, Xiaoyun
Luo, Yihuan
Tan, Chao
Liu, Bihu
Tang, Peng
Liao, Qian
Liu, Shun
Yu, Hongping
Huang, Dongping
Zeng, Xiaoyun
Qiu, Xiaoqiang
author_sort Mo, Meile
collection PubMed
description BACKGROUND: Increasing evidence shows that liver-specific long non-coding RNAs (lncRNAs) play important roles in the development of hepatocellular carcinoma (HCC). We identified a novel liver-specific lncRNA, FAM99A, and examined its clinical significance and biological functions in HCC. METHODS: The expression level and clinical value of FAM99A in HCC were examined using The Cancer Genome Atlas (TCGA), International Cancer Genome Consortium (ICGC), and Gene Expression Omnibus (GEO) databases, and were further verified using quantitative real-time polymerase chain reaction (qRT–PCR) in our HCC cohort. Univariate and multivariate Cox proportional hazards regression models were also applied to identify independent prognostic indicators for HCC patients. Cell counting kit-8, colony formation, and Transwell assays were performed to evaluate the effects of FAM99A on the proliferation, migration, and invasion abilities of HCC cells in vitro. A subcutaneous xenograft tumor model was implemented to determine the effect of FAM99A on the tumor growth of HCC cells in vivo. RNA pull-down and mass spectrometry assays were performed to reveal the potential molecular mechanisms of FAM99A in HCC. RESULTS: The three public online databases and qRT–PCR data showed that FAM99A was frequently downregulated in HCC tissues and inversely correlated with microvascular invasion and advanced histological grade of HCC patients. Kaplan–Meier survival analysis indicated that decreased FAM99A was significantly associated with poor overall survival of HCC patients based on TCGA database (P = 0.040), ICGC data portal (P < 0.001), and our HCC cohort (P = 0.010). A multivariate Cox proportional hazards regression model based on our HCC cohort suggested that FAM99A was an independent prognostic factor of overall survival for HCC patients (hazard ratio: 0.425, P = 0.039). Upregulation of FAM99A suppressed the proliferation, colony formation, migration, and invasion capacities of HCC cells in vitro, and knockdown of FAM99A had the opposite effects. A subcutaneous xenograft tumor model demonstrated that overexpression of FAM99A significantly inhibited the tumor growth of HCC cells in vivo. Seven tumor-related proteins (PCBP1, SRSF5, SRSF6, YBX1, IGF2BP2, HNRNPK, and HNRNPL) were recognized as possible FAM99A-binding proteins by the RNA pull-down and mass spectrometry assays. CONCLUSION: Our results suggest that FAM99A exerts cancer-inhibiting effects on HCC progression, and it may be a promising prognostic indicator for HCC patients. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-022-10186-2.
format Online
Article
Text
id pubmed-9609286
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-96092862022-10-28 Liver-specific lncRNA FAM99A may be a tumor suppressor and promising prognostic biomarker in hepatocellular carcinoma Mo, Meile Ma, Xiaoyun Luo, Yihuan Tan, Chao Liu, Bihu Tang, Peng Liao, Qian Liu, Shun Yu, Hongping Huang, Dongping Zeng, Xiaoyun Qiu, Xiaoqiang BMC Cancer Research BACKGROUND: Increasing evidence shows that liver-specific long non-coding RNAs (lncRNAs) play important roles in the development of hepatocellular carcinoma (HCC). We identified a novel liver-specific lncRNA, FAM99A, and examined its clinical significance and biological functions in HCC. METHODS: The expression level and clinical value of FAM99A in HCC were examined using The Cancer Genome Atlas (TCGA), International Cancer Genome Consortium (ICGC), and Gene Expression Omnibus (GEO) databases, and were further verified using quantitative real-time polymerase chain reaction (qRT–PCR) in our HCC cohort. Univariate and multivariate Cox proportional hazards regression models were also applied to identify independent prognostic indicators for HCC patients. Cell counting kit-8, colony formation, and Transwell assays were performed to evaluate the effects of FAM99A on the proliferation, migration, and invasion abilities of HCC cells in vitro. A subcutaneous xenograft tumor model was implemented to determine the effect of FAM99A on the tumor growth of HCC cells in vivo. RNA pull-down and mass spectrometry assays were performed to reveal the potential molecular mechanisms of FAM99A in HCC. RESULTS: The three public online databases and qRT–PCR data showed that FAM99A was frequently downregulated in HCC tissues and inversely correlated with microvascular invasion and advanced histological grade of HCC patients. Kaplan–Meier survival analysis indicated that decreased FAM99A was significantly associated with poor overall survival of HCC patients based on TCGA database (P = 0.040), ICGC data portal (P < 0.001), and our HCC cohort (P = 0.010). A multivariate Cox proportional hazards regression model based on our HCC cohort suggested that FAM99A was an independent prognostic factor of overall survival for HCC patients (hazard ratio: 0.425, P = 0.039). Upregulation of FAM99A suppressed the proliferation, colony formation, migration, and invasion capacities of HCC cells in vitro, and knockdown of FAM99A had the opposite effects. A subcutaneous xenograft tumor model demonstrated that overexpression of FAM99A significantly inhibited the tumor growth of HCC cells in vivo. Seven tumor-related proteins (PCBP1, SRSF5, SRSF6, YBX1, IGF2BP2, HNRNPK, and HNRNPL) were recognized as possible FAM99A-binding proteins by the RNA pull-down and mass spectrometry assays. CONCLUSION: Our results suggest that FAM99A exerts cancer-inhibiting effects on HCC progression, and it may be a promising prognostic indicator for HCC patients. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-022-10186-2. BioMed Central 2022-10-26 /pmc/articles/PMC9609286/ /pubmed/36289466 http://dx.doi.org/10.1186/s12885-022-10186-2 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Mo, Meile
Ma, Xiaoyun
Luo, Yihuan
Tan, Chao
Liu, Bihu
Tang, Peng
Liao, Qian
Liu, Shun
Yu, Hongping
Huang, Dongping
Zeng, Xiaoyun
Qiu, Xiaoqiang
Liver-specific lncRNA FAM99A may be a tumor suppressor and promising prognostic biomarker in hepatocellular carcinoma
title Liver-specific lncRNA FAM99A may be a tumor suppressor and promising prognostic biomarker in hepatocellular carcinoma
title_full Liver-specific lncRNA FAM99A may be a tumor suppressor and promising prognostic biomarker in hepatocellular carcinoma
title_fullStr Liver-specific lncRNA FAM99A may be a tumor suppressor and promising prognostic biomarker in hepatocellular carcinoma
title_full_unstemmed Liver-specific lncRNA FAM99A may be a tumor suppressor and promising prognostic biomarker in hepatocellular carcinoma
title_short Liver-specific lncRNA FAM99A may be a tumor suppressor and promising prognostic biomarker in hepatocellular carcinoma
title_sort liver-specific lncrna fam99a may be a tumor suppressor and promising prognostic biomarker in hepatocellular carcinoma
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9609286/
https://www.ncbi.nlm.nih.gov/pubmed/36289466
http://dx.doi.org/10.1186/s12885-022-10186-2
work_keys_str_mv AT momeile liverspecificlncrnafam99amaybeatumorsuppressorandpromisingprognosticbiomarkerinhepatocellularcarcinoma
AT maxiaoyun liverspecificlncrnafam99amaybeatumorsuppressorandpromisingprognosticbiomarkerinhepatocellularcarcinoma
AT luoyihuan liverspecificlncrnafam99amaybeatumorsuppressorandpromisingprognosticbiomarkerinhepatocellularcarcinoma
AT tanchao liverspecificlncrnafam99amaybeatumorsuppressorandpromisingprognosticbiomarkerinhepatocellularcarcinoma
AT liubihu liverspecificlncrnafam99amaybeatumorsuppressorandpromisingprognosticbiomarkerinhepatocellularcarcinoma
AT tangpeng liverspecificlncrnafam99amaybeatumorsuppressorandpromisingprognosticbiomarkerinhepatocellularcarcinoma
AT liaoqian liverspecificlncrnafam99amaybeatumorsuppressorandpromisingprognosticbiomarkerinhepatocellularcarcinoma
AT liushun liverspecificlncrnafam99amaybeatumorsuppressorandpromisingprognosticbiomarkerinhepatocellularcarcinoma
AT yuhongping liverspecificlncrnafam99amaybeatumorsuppressorandpromisingprognosticbiomarkerinhepatocellularcarcinoma
AT huangdongping liverspecificlncrnafam99amaybeatumorsuppressorandpromisingprognosticbiomarkerinhepatocellularcarcinoma
AT zengxiaoyun liverspecificlncrnafam99amaybeatumorsuppressorandpromisingprognosticbiomarkerinhepatocellularcarcinoma
AT qiuxiaoqiang liverspecificlncrnafam99amaybeatumorsuppressorandpromisingprognosticbiomarkerinhepatocellularcarcinoma